UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Rev. 1450

P O Box 1450 Alexandria, Virgima 22313-1450

NOTICE OF ALLOWANCE AND FEE(S) DUE

26161 7590 04/25/2008

FISH & RICHARDSON PC P.O. BOX 1022

MINNEAPOLIS, MN 55440-1022

EXAMINER
NOBLE, MARCIA STEPHENS

ART UNIT PAPER NUMBER

1632 DATE MAILED: 04/25/2008

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/516,603 | 06/08/2005 | Tatsuhiko Kodama | 14875-137US1 | 5647 |

TITLE OF INVENTION: METHOD OF CONSTRUCTING ANTIBODY

| APPLN. TYPE | SMALL ENTITY | ISSUE FEE DUE | PUBLICATION FEE DUE | PREV. PAID ISSUE FEE | TOTAL FEE(8) DUE | DATE DUE |
|----------------|--------------|---------------|---------------------|----------------------|------------------|------------|
| nonprovisional | NO | \$1440 | \$300 | \$0 | \$1740 | 07/25/2008 |

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

| INSTRUCTIONS: This appropriate. All further indicated unless correcte maintenance fee notifical | form should be used I correspondence including d below or directed off tions. | or tran | smitting the ISSU Patent, advance or in Block 1, by (a | | | | | | tould be completed where correspondence address as rate "FEE ADDRESS" for |
|--|---|---|---|---|--|--|---------------------------|--|--|
| CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) | | | | | Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. | | | | |
| FISH & RICHA P.O. BOX 1022 MINNEAPOLIS | | /2008 | | | I bar | Cer | tificate | of Mailing or Transı | |
| | | | | | | | | | (Depositor's name) |
| | | | | | | | | | (Signature) |
| | | | | | L | | | | (Date) |
| APPLICATION NO. | FILING DATE | | | FIRST NAMED INVEN | TOR | | ATTO | RNEY DOCKET NO. | CONFIRMATION NO. |
| 10/516,603 | 06/08/2005 | | | Tatsuhiko Kodam | а | | | 4875-137US1 | 5647 |
| TITLE OF INVENTION | : METHOD OF CONST | RUCT | ING ANTIBODY | | | | | | |
| APPLN. TYPE | SMALL ENTITY | IS | SUE FEE DUE | PUBLICATION FEE D | UE. | PREV. PAID ISSUE | FEE | TOTAL FEE(S) DUE | DATE DUE |
| nonprovisional | NO | | \$1440 | \$300 | | \$0 | | \$1740 | 07/25/2008 |
| EXAM | INER | | ART UNIT | CLASS-SUBCLASS | | | | | |
| NOBLE, MARC | IA STEPHENS | | 1632 | 800-006000 | | | | | |
| "Fee Address" ind. PTO/SB/47; Rev 03-0 Number is required. 3. ASSIGNEE NAME A | ess an assignee is ident h in 37 CFR 3.II. Comp | " Indica ed. Use | ation form e of a Customer E PRINTED ON T | | ingle or a attor Il be p or typ he pa g an a | ety, c firm (having as a gent) and the name neys or agents. If op- printed. e) stent. If an assigna- ussignment. | memb es of u no nan | er a 2 p to e is 3 lentified below, the do | ocument has been filed for |
| Please check the appropri | iate assignee category or | catego | ories (will not be pr | inted on the patent): | | Individual 🚨 Co | rporati | on or other private gro | up entity 🚨 Government |
| Advance Order - # | o small entity discount j | | ed) | A check is enclos Payment by credi The Director is he | ed. t care | i. Form PTO-2038 | is atta | required fee(s), any def | |
| | s SMALL ENTITY state | ıs. See | 37 CFR I.27. | | | | | ITTY status. See 37 CF | |
| NOTE: The Issue Fee an interest as shown by the | d Publication Fee (if req ecords of the United Sta | uired) v tes Pat | will not be accepted ent and Trademark | I from anyone other th Office. | nan th | ne applicant; a regi | stered . | attorney or agent; or th | e assignee or other party in |
| Authorized Signature | | | | | | Date | | | |
| Typed or printed name | | | | | | Registration N | | | |
| This collection of inform an application. Confident submitting the completes this form and/or suggesti Box 1450, Alexandria, V Alexandria, Virginia 223 | ation is required by 37 C tiality is governed by 35 I application form to the ons for reducing this bu irginia 22313-1450. DO 13-1450. | FR 1.3 U.S.C. USPT rden, sl D NOT | 11. The informatic . 122 and 37 CFR O. Time will vary hould be sent to the SEND FEES OR O | n is required to obtain 1.14. This collection i depending upon the i chief Information O COMPLETED FORM | or re s esti indivi ffice S TC | etain a benefit by the imated to take 12 r idual case. Any co r, U.S. Patent and D THIS ADDRESS | ninute: mmen Trader | ic which is to file (and to complete, including s on the amount of tin nark Office, U.S. Depa D TO: Commissioner f | by the USPTO to process) g gathering, preparing, and ne you require to complete atment of Commerce, P.O. for Patents, P.O. Box 1450, |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|-----------------|----------------|------------------------|---------------------|------------------|--|
| 10/516,603 | 06/08/2005 | Tatsuhiko Kodama | 14875-137US1 | 5647 | |
| 26161 | 590 04/25/2008 | | EXAMINER | | |
| FISH & RICHA | RDSON PC | NOBLE, MARCIA STEPHENS | | | |
| P.O. BOX 1022 | | ART UNIT | PAPER NUMBER | | |
| MINNEAPOLIS, | MN 55440-1022 | 1632 | | | |

DATE MAILED: 04/25/2008

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Notice of Allowability

| Application No. | Applicant(s) | |
|-----------------|---------------|--|
| 10/516,603 | KODAMA ET AL. | |
| Examiner | Art Unit | |
| Marcia S. Noble | 1632 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-All claims being allowable, PROSECUTION ON THE MERTIS IS (OR REMAINS) CLOSED in this application. If not included
herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS
NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
of the Office or upon petition by the applicant. See 37 CFR 133 and MPEP 1308.

- This communication is responsive to the RCE, filed 9/10/2007.
- 2. The allowed claim(s) is/are 19 and 21.
- 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a)

 All b)

 Some* c)

 None of the:
 - 1. A Certified copies of the priority documents have been received.
 - 2. Certified copies of the priority documents have been received in Application No. _____
 - Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 - * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDOMMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

- A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
- 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) Thereto or 2) to Paper No./Mail Date
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- 1. Notice of References Cited (PTO-892)
- 2.
 Notice of Draftperson's Patent Drawing Review (PTO-948)
- Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 9/10/2007
- Examiner's Comment Regarding Requirement for Deposit of Biological Material
- 5. Notice of Informal Patent Application
- Interview Summary (PTO-413), Paper No./Mail Date .
- 7. X Examiner's Amendment/Comment
- 8.

 Examiner's Statement of Reasons for Allowance
- 9. Other _____.

Art Unit: 1632

DETAILED ACTION

Continued Examination Under 37 CFR 1.1141

 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection.
 Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114.
 Applicant's submission filed on 9/10/2007 has been entered.

Status of Claims

Claims 1-3 and 10-21 are pending. Claims 19 is amended, claims 4 and
 6-8 are canceled, and claim 21 is newly added by amendment filed 9/10/2007.

Election/Restrictions

Claims 1-3, 10-18 and 20 were previously withdrawn from further
consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected
subject matter, there being no allowable generic or linking claim. Election was
made without traverse in the reply filed on 3/29/2006.

Claims 19 and 21 are under consideration.

Information Disclosure Statement

 The information disclosure statements submitted on 9/25/2007 and 10/24/2007 were filed after the mailing date of the Request for Continued Application/Control Number: 10/516.603

Art Unit: 1632

Examination on 9/10/2007. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

The information disclosure statement filed 10/3/2007 was not considered because it is a duplicate of the information disclosure statement filed 10/24/2007.

The information disclosure statements submitted on 9/10/2007 and 10/24/2007 was filed after the mailing date of the Final Office Action on 3/9/2007. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. However, Cite No. AB on page 1 of the IDS was not considered because it was in a language other than English and therefore was crossed out.

Claim Rejections - 35 USC § 112, 1st Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Scope of Enablement

 The rejection of claims 4 and 6-8 under 35 U.S.C. 112, first paragraph, because the specification partially enables the instant claims, is withdrawn.

Applicant canceled the instant claims rendering the rejection moot. Therefore, the rejection is withdrawn.

Application/Control Number: Page 4

10/516,603 Art Unit: 1632

New Matter

 The rejection of claims 4, 6-8 and 19, under 35 U.S.C. 112, first paragraph for reciting the new matter, "in an expressible manner", is withdrawn.

Applicant canceled claims 4 and 6-8, rendering their rejection moot.

Applicant amended claim 19 to remove the recited new matter. Therefore, the rejection is withdrawn.

Claim Rejections - 35 USC § 112, 2nd Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

 The rejection of claims 4 and 6-8, under 35 U.S.C. 112, second paragraph, as being indefinite for the limitation "the transgenic mouse animal" in steps c) and d), is withdrawn.

Applicant canceled the instant claims rendering the rejection moot. Therefore, the rejection is withdrawn.

8. No rejections remain of record, and the instant claims are free of the art.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Anita Meiklejohn on 4/15/2008.

The application has been amended as follows:

The specification is amended as follows:

In the claims:

Claims 1-3, 10-18, and 20 are canceled.

Claim 19 is rewritten as follows:

19. A method for producing an antibody against PepT1, wherein the method comprises the steps of: (a) preparing a baculovirus that comprises a DNA which encodes PepT1 or a fragment thereof and expresses PepT1 or a fragment thereof; (b) infecting a cultured host cell with the baculovirus of (a) to obtain a budding virus that expresses PepT1 or a fragment thereof; (c) producing a transgenic mouse that comprises in its genome a gene encoding a baculovirus membrane protein gp64 wherein the mouse expresses the baculovirus membrane protein gp64 and has immunotolerance to gp64; (d) immunizing the transgenic mouse of (c) with the budding virus of (b) or PepT1 or its fragment;

Application/Control Number: Page 6

10/516,603 Art Unit: 1632

and (e) recovering an antibody recognizing PepT1 from the immunized transgenic mouse.

Claim 21 is rewritten as follows:

21. A method for producing an antibody against an antigen, wherein the method comprises the steps of: (a) preparing a baculovirus that comprises a DNA which encodes an antigen or an epitope thereof and expresses the antigen or epitope thereof; (b) infecting a cultured host cell with the baculovirus of (a) to obtain a budding virus that expresses the antigen or epitope thereof; (c) producing a transgenic mouse that comprises in its genome a gene encoding a baculovirus membrane protein gp64 wherein the transgenic mouse expresses the baculovirus membrane protein gp64 and has immunotolerance to gp64; (d) immunizing the transgenic mouse of (c) with the budding virus of (b); and (e) recovering an antibody specific for the antigen or epitope thereof from the immunized transgenic mouse.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marcia S. Noble whose telephone number is (571) 272-5545. The examiner can normally be reached on M-F 9 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/516,603

Page 7

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (tollfree). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Marcia S. Noble

/Peter Paras, Jr./ Peter Paras, Jr.

Supervisory Patent Examiner, Art Unit 1632